These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32690263)

  • 61. HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
    Duffy JL; Kirk BA; Kevin NJ; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3323-6. PubMed ID: 12951118
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex.
    Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898
    [TBL] [Abstract][Full Text] [Related]  

  • 63. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
    Garg R; Bhhatarai B
    Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues.
    Lockbaum GJ; Rusere LN; Henes M; Kosovrasti K; Rao DN; Spielvogel E; Lee SK; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
    Eur J Med Chem; 2023 Sep; 257():115501. PubMed ID: 37244161
    [TBL] [Abstract][Full Text] [Related]  

  • 67. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
    Yedidi RS; Maeda K; Fyvie WS; Steffey M; Davis DA; Palmer I; Aoki M; Kaufman JD; Stahl SJ; Garimella H; Das D; Wingfield PT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4920-7. PubMed ID: 23877703
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.
    Chang YC; Yu X; Zhang Y; Tie Y; Wang YF; Yashchuk S; Ghosh AK; Harrison RW; Weber IT
    J Med Chem; 2012 Apr; 55(7):3387-97. PubMed ID: 22401672
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.
    Das D; Koh Y; Tojo Y; Ghosh AK; Mitsuya H
    J Chem Inf Model; 2009 Dec; 49(12):2851-62. PubMed ID: 19928916
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.
    Yedidi RS; Muhuhi JM; Liu Z; Bencze KZ; Koupparis K; O'Connor CE; Kovari IA; Spaller MR; Kovari LC
    Biochem Biophys Res Commun; 2013 Sep; 438(4):703-8. PubMed ID: 23921229
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
    Gao BL; Zhang CM; Yin YZ; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3730-3. PubMed ID: 21555220
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds.
    Weber J; Majer P; Litera J; Urban J; Soucek M; Vondrásek J; Konvalinka J; Novek P; Sedlácek J; Strop P; Kräusslich HG; Pichová I
    Arch Biochem Biophys; 1997 May; 341(1):62-9. PubMed ID: 9143353
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors.
    Ghosh AK; Chapsal BD; Baldridge A; Ide K; Koh Y; Mitsuya H
    Org Lett; 2008 Nov; 10(22):5135-8. PubMed ID: 18928291
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.
    Ghosh AK; Mishevich JL; Kovela S; Shaktah R; Ghosh AK; Johnson M; Wang YF; Wong-Sam A; Agniswamy J; Amano M; Takamatsu Y; Hattori SI; Weber IT; Mitsuya H
    Eur J Med Chem; 2023 Jul; 255():115385. PubMed ID: 37150084
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
    Ghosh AK; Krishnan K; Walters DE; Cho W; Cho H; Koo Y; Trevino J; Holland L; Buthod J
    Bioorg Med Chem Lett; 1998 Apr; 8(8):979-82. PubMed ID: 9871524
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
    Ghosh AK; Parham GL; Martyr CD; Nyalapatla PR; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2013 Sep; 56(17):6792-802. PubMed ID: 23947685
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular recognition of cyclic urea HIV-1 protease inhibitors.
    Ala PJ; DeLoskey RJ; Huston EE; Jadhav PK; Lam PY; Eyermann CJ; Hodge CN; Schadt MC; Lewandowski FA; Weber PC; McCabe DD; Duke JL; Chang CH
    J Biol Chem; 1998 May; 273(20):12325-31. PubMed ID: 9575185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.